FDA Approves Two Low-Cost Abortion Pill Versions, Ending Monopoly
The FDA has approved two low-cost versions of the abortion medication mifepristone, ending a long-standing monopoly and increasing access to the drugs. Evita Solutions received approval for its version, with another generic's approval also announced, though the company remains unnamed. This move comes amidst pressure from abortion opponents on President Trump's health officials.
Evita Solutions, a drugmaker, has been granted FDA approval for its affordable form of mifepristone. The company filed its application four years ago and expects the drug to hit the market in January next year. This approval breaks Danco Laboratories' monopoly on the medication, with another generic also approved, though the manufacturer is yet to be named. The FDA's decision comes despite opposition from Students for Life Action and Republican Sen. Josh Hawley.
The FDA's approval process for generic drugs is usually straightforward. However, under the current leadership, decisions on vaccines have been repeatedly delayed. Despite this, FDA officials have stated their limited discretion in deciding whether to approve a generic drug.
With the FDA's approval of two low-cost versions of mifepristone, access to the abortion medication is set to increase. Evita Solutions' drug is expected to launch in January, while another generic will follow soon. This move, however, has sparked criticism from abortion opponents and may face further challenges amidst pressure on President Trump's health officials.
